Score:
5.5/10
Analyze what earned this score 🔥
Topper’s Copy
GS2
Governance
10 marks
The recurring incidents of contamination in pharmaceutical products like cough syrups raise serious concerns about India’s drug regulatory framework. Discuss the systemic challenges in ensuring drug safety and suggest measures to strengthen pharmaceutical quality control in India.
Student’s Answer
Evaluation by SuperKalam
Demand of the Question
- Discuss systemic challenges in drug safety
- Suggest measures to strengthen pharmaceutical quality control
- Link to recent contamination incidents
- Focus on regulatory framework issues
What you wrote:
India, hailed as the "Pharmacy of the world" has recently faced global outrage & a health crisis when several deaths in Madhya Pradesh and Rajasthan were linked to Coldrif syrup containing diethylene glycol (DEG) - a toxic solvent.
Similar cases in Gambia (2022) and Uzbekistan (2024) show a recurring Pattern of Pharmaceutical Contamination, exposing serious flaws in India's drug delivery system.
→ while India's pharma exports are globally vital, its regulatory architecture remains riddled with systemic weaknesses.
India, hailed as the "Pharmacy of the world" has recently faced global outrage & a health crisis when several deaths in Madhya Pradesh and Rajasthan were linked to Coldrif syrup containing diethylene glycol (DEG) - a toxic solvent.
Similar cases in Gambia (2022) and Uzbekistan (2024) show a recurring Pattern of Pharmaceutical Contamination, exposing serious flaws in India's drug delivery system.
→ while India's pharma exports are globally vital, its regulatory architecture remains riddled with systemic weaknesses.
Suggestions to improve:
- Can open with regulatory statistics (e.g., India has over 3,000 pharmaceutical companies but only 1,500 drug inspectors)
- Could include a brief mention of the current regulatory structure (e.g., CDSCO as central authority, 36 state regulators)
What you wrote:
[DRAWING: A flowchart illustrating the systemic challenges and measures for India's drug regulatory framework.]
Systemic Challenges
* Fragmented regulation between CDSCO and State Drug Authorities
* lack of robust quality check and Post-market surveillance.
* Weak Penalties under the Drugs and Cosmetics Act, 1990
* Poor GMP Compliance among small manufacturers
* Inadequate manpower and infrastructure - only 47 drug testing labs nationwide
[DRAWING: A flowchart illustrating the systemic challenges and measures for India's drug regulatory framework.]
Systemic Challenges
* Fragmented regulation between CDSCO and State Drug Authorities
* lack of robust quality check and Post-market surveillance.
* Weak Penalties under the Drugs and Cosmetics Act, 1990
* Poor GMP Compliance among small manufacturers
* Inadequate manpower and infrastructure - only 47 drug testing labs nationwide
Suggestions to improve:
- Can elaborate on fragmented regulation (e.g., varying standards across states leading to quality disparities in 36 different jurisdictions)
- Could highlight raw material procurement issues (e.g., 70% API dependence on China affecting quality control)
- Can include technological gaps (e.g., lack of end-to-end digital tracking systems in supply chain)
- Could mention resource constraints (e.g., one drug inspector for 200 manufacturing units against global norm of 1:50)
What you wrote:
Measures
* Establish unified National Drug Regulatory Authority with Digital Traceability.
* Enforce mandatory GMP and third party audits.
* Strengthen testing infrastructure and workforce.
* Expand pharma-vigilance and recall mechanisms.
Measures
* Establish unified National Drug Regulatory Authority with Digital Traceability.
* Enforce mandatory GMP and third party audits.
* Strengthen testing infrastructure and workforce.
* Expand pharma-vigilance and recall mechanisms.
Suggestions to improve:
- Can detail GMP implementation (e.g., regular surprise inspections, risk-based assessment)
- Could include capacity building measures (e.g., specialized training for drug inspectors)
- Can suggest blockchain integration for supply chain transparency
- Could mention international collaboration (e.g., harmonization with WHO GMP guidelines)
What you wrote:
Way forward:- India must adopt a technology-driven, transparent, and accountable regulatory framework, backed by ethical corporate responsibility and global corporation, to ensure drug safety, public trust, and sustain its role as The Pharmacy of the World.
Way forward:- India must adopt a technology-driven, transparent, and accountable regulatory framework, backed by ethical corporate responsibility and global corporation, to ensure drug safety, public trust, and sustain its role as The Pharmacy of the World.
Suggestions to improve:
- Can conclude with specific targets (e.g., achieving WHO GMP compliance in 80% of manufacturing units by 2025)
- Could emphasize the dual goal of public safety and maintaining India's global pharmaceutical leadership
Marks: 5.5/10
Demand of the Question
- Discuss systemic challenges in drug safety
- Suggest measures to strengthen pharmaceutical quality control
- Link to recent contamination incidents
- Focus on regulatory framework issues
What you wrote:
India, hailed as the "Pharmacy of the world" has recently faced global outrage & a health crisis when several deaths in Madhya Pradesh and Rajasthan were linked to Coldrif syrup containing diethylene glycol (DEG) - a toxic solvent.
Similar cases in Gambia (2022) and Uzbekistan (2024) show a recurring Pattern of Pharmaceutical Contamination, exposing serious flaws in India's drug delivery system.
→ while India's pharma exports are globally vital, its regulatory architecture remains riddled with systemic weaknesses.
India, hailed as the "Pharmacy of the world" has recently faced global outrage & a health crisis when several deaths in Madhya Pradesh and Rajasthan were linked to Coldrif syrup containing diethylene glycol (DEG) - a toxic solvent.
Similar cases in Gambia (2022) and Uzbekistan (2024) show a recurring Pattern of Pharmaceutical Contamination, exposing serious flaws in India's drug delivery system.
→ while India's pharma exports are globally vital, its regulatory architecture remains riddled with systemic weaknesses.
Suggestions to improve:
- Can open with regulatory statistics (e.g., India has over 3,000 pharmaceutical companies but only 1,500 drug inspectors)
- Could include a brief mention of the current regulatory structure (e.g., CDSCO as central authority, 36 state regulators)
More Challenges
View All- View Challenge
GS2
Indian Polity
15 Mar, 2026
“India–Canada relations are witnessing a pragmatic reset driven by strategic, economic, and energy considerations.”
Discuss the significance of the recent India–Canada agreements, particularly in the areas of nuclear energy and critical minerals cooperation. - View Challenge
GS2
Indian Polity
Yesterday
“Passive euthanasia in India reflects the evolving interpretation of the Right to Life under Article 21 of the Constitution.”
Discuss in the light of recent Supreme Court developments and the ethical concerns surrounding end-of-life decisions. - View Challenge
GS2
International Relations
13 Mar, 2026
“The Strait of Hormuz remains one of the most critical maritime chokepoints in the global energy supply chain.”
Discuss its geopolitical significance and analyse the implications of instability in the region for India’s energy security.
